The Alliance for Regenerative Medicine (ARM), the international advocacy organization representing the cell and gene therapy and broader regenerative medicine sector, today submitted its comments regarding the modification of Medicare’s New Technology Add-on Payment Program (NTAP) to reflect the potential added value of regenerative medicine products to the healthcare system. These comments were drafted in response to the proposed changes by the Centers for Medicare and Medicaid Services (CMS) to the Hospital Inpatient Prospective Payment System, issued August 2017.
ARM’s comments, available here, detail recommendations to improve the current NTAP and overall MS-DRG system with a focus on creating a methodology and system that balances appropriate access and cost-effective care to new and innovative therapies, including those comprising the regenerative medicine sector: gene therapies; cell therapies; and tissue engineered products.
In its comments, ARM makes four main recommendations regarding the NTAP program:
CMS’s proposed changes to the Hospital Inpatient Prospective Payment System are available here.
About the Alliance for Regenerative Medicine:
The Alliance for Regenerative Medicine (ARM) is a global, multi-stakeholder organization that promotes innovation, growth, and delivery of transformative treatments or cures for patients suffering from chronic, debilitating, and often life-threatening diseases, many of which are rare diseases. ARM convenes all stakeholders with an interest in regenerative and advanced therapies to provide a unified voice for our 290+ member organizations, including companies – especially small- to medium-sized enterprises (SMEs); academic/research institutions; non-profit organizations; patient advocacy organizations, and other members of the global advanced therapies community. The organization’s aim is to connect all parts of the innovation lifecycle to address current unmet medical needs of patients, particularly through supporting commercialization objectives via legislative and policy frameworks that enable next generation therapies to reach those who need them. To learn more about ARM, visit http://www.alliancerm.org.